Inspira Technologies OXY BHN Ltd. has announced a strategic expansion into liquid biopsy diagnostics through the proposed acquisition of an advanced liquid biopsy platform. As part of the transaction, Inspira will receive a $15 million equity investment, with up to $12 million allocated to support the growth and commercialization of its existing respiratory and blood-monitoring technologies. The acquisition will see Inspira issue up to 40% of its share capital to integrate the new diagnostics platform, aiming to drive long-term growth while maintaining value for current shareholders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622278) on January 08, 2026, and is solely responsible for the information contained therein.
Comments